...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

Is the ineptness something to do with having DMcC being Chairman of both boards and the CEO of both entities, Zentih and Resverlogix.  We have plenty of experience with all the other professionals who are at the mangement level within both companies and on these boards. DMcC is a cave man looking at a coke can when it comes to the science. He can parrot the language but as a none scientist is at a loss. The direction of these companies is not coming from our CEO imo! We must have been stagnated and mired in irrational exuberance for years by the Team at large! Diffcult to believe such but history supports this notion. We certainly are professionals at acquiring debt, failing to meet our goals, venturing into to lack luster deals with our IP at risk, and creating sustaining value is unattainable.!

The problem possibly,,,our team see a deluded or an unrealistic future, such as being a medium sized Pharma,,,,the reality has been,,having a poor business model,,focusing on one epigenetic drug and not pushing out several others to established Pharmas,,,,the shareholders experience nothing but an ever depreciating investment which clearly has been a devestment!,,,Bottom line,,,,GREED,,,,is the controlling emotion within!!!

Share
New Message
Please login to post a reply